0 reactions
🧬 Moderna and Merck said August 19 that their personalized mRNA treatment, intismeran, met key goals in a late-stage trial for high-risk melanoma after surgery. The combination with Merck’s Keytruda was reported to reduce recurrence or spread compared with Keytruda alone.
Intismeran is made to target mutations found in an individual patient’s tumor. That makes it a therapeutic cancer treatment designed to help the immune system recognize cancer cells, rather than a preventive vaccine or a one-size-fits-all cancer shot.
The phase 3 study involved more than 1,100 patients, according to Axios. The companies said the treatment showed a clinically meaningful improvement and that its safety profile was consistent with earlier studies, with no new risks reported. 💉
Important limits remain: detailed trial data have not yet been released, and the companies did not report overall-survival results or the length of time patients remained free of recurrence. Intismeran is still investigational and is not approved for routine use.
The companies plan to present fuller results at a medical meeting and are discussing the treatment with regulators. The result also drew a sharp market response, with Moderna and Merck shares rising on August 19.
https://nutanica.com/Intismeran
Intismeran is made to target mutations found in an individual patient’s tumor. That makes it a therapeutic cancer treatment designed to help the immune system recognize cancer cells, rather than a preventive vaccine or a one-size-fits-all cancer shot.
The phase 3 study involved more than 1,100 patients, according to Axios. The companies said the treatment showed a clinically meaningful improvement and that its safety profile was consistent with earlier studies, with no new risks reported. 💉
Important limits remain: detailed trial data have not yet been released, and the companies did not report overall-survival results or the length of time patients remained free of recurrence. Intismeran is still investigational and is not approved for routine use.
The companies plan to present fuller results at a medical meeting and are discussing the treatment with regulators. The result also drew a sharp market response, with Moderna and Merck shares rising on August 19.
https://nutanica.com/Intismeran
| 2,000 mlx | |
| 4 | |
| 0 |